Results 71 to 80 of about 1,273,410 (345)

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

Impact of COVID-19 on the time to counseling and treatment of prostate cancer

The Aging Male
Purpose This study investigates how the COVID-19 pandemic (CP) impacted the timeline between initial diagnosis (ID) of prostate carcinoma and subsequent therapy consultation (TC) or radical prostatectomy (RP) due to the implementation of a “minimal ...
Dejan K. Filipas, Randi M. Pose, Phillip Marks, Pierre Tennstedt, Burkhard Beyer, Derya Tilki, Hendrik Isbarn, Tobias Maurer, Tim A. Ludwig, Hans Heinzer, Thomas Steuber   +10 more
doaj   +1 more source

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

A model for predicting overall survival in bladder cancer patients with signet ring cell carcinoma: a population-based study

European Journal of Medical Research, 2023
Introduction This study is to examine the predictors of survival and to construct a nomogram for predicting the overall survival (OS) of primary bladder signet ring cell carcinoma (SRCC) patients based on the analysis of the Surveillance, Epidemiology ...
Liang Liu, Chuangui Li, Qiang Wang, Haibo Yuan, Yuanyuan Wang   +4 more
doaj   +1 more source

Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer

New England Journal of Medicine, 2018
BACKGROUND Men with nonmetastatic, castration‐resistant prostate cancer and a rapidly rising prostate‐specific antigen (PSA) level are at high risk for metastasis.
M. Hussain, K. Fizazi, F. Saad, P. Rathenborg, N. Shore, U. Ferreira, P. Ivashchenko, E. Demirhan, K. Modelska, D. Phung, A. Krivoshik, C. Sternberg   +11 more
semanticscholar   +1 more source

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

Molecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
wiley   +1 more source

Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?

Frontiers in Psychology, 2020
BackgroundThe psychological burden possibly deriving from not immediately undergoing radical treatment for prostate cancer (PCa) could be a potential disadvantage of active surveillance (AS), especially in the eve of some relevant clinical exams [i.e ...
Maria Francesca Alvisi, Paola Dordoni, Tiziana Rancati, Barbara Avuzzi, Nicola Nicolai, Fabio Badenchini, Letizia De Luca, Tiziana Magnani, Cristina Marenghi, Julia Menichetti, Villa Silvia, Zollo Fabiana, Salvioni Roberto, Valdagni Riccardo, Valdagni Riccardo, Valdagni Riccardo, Bellardita Lara, the Prostate Cancer Multidisciplinary Clinic Working Group   +17 more
doaj   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Journal of Clinical Oncology, 2016
PURPOSE Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to succeed those from prior ...
H. Scher, M. Morris, W. Stadler, C. Higano, E. Basch, K. Fizazi, E. Antonarakis, T. Beer, M. Carducci, K. Chi, P. Corn, J. D. de Bono, R. Dreicer, D. George, E. Heath, M. Hussain, W. Kelly, Glenn Liu, C. Logothetis, D. Nanus, M. Stein, D. Rathkopf, S. Slovin, C. Ryan, O. Sartor, E. Small, Matthew R. Smith, C. Sternberg, M. Taplin, G. Wilding, P. Nelson, L. Schwartz, S. Halabi, P. Kantoff, A. Armstrong   +34 more
semanticscholar   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source